EU approved one-fifth-dose on Monkeypox vaccination due to shortage
- Novavax COVID-19 vaccine gets emergency use authorization in US
- FDA Fast Track Designation = Immediate Surge in Stock Prices?
- France Resumes COVID-19 Vaccination Campaign
- Why did Early American Settlers stuggling with “Prairie Madness”?
- Largest Healthcare Group in the US Initiates Strike
- Targeting Sugar Molecules in Sugar-Immune Therapy
EU approved one-fifth-dose on Monkeypox vaccination due to shortage
- Cardiovascular Diseases Linked to COVID-19 Infections
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
EU approved one-fifth-dose on Monkeypox vaccination due to shortage.
The monkeypox vaccine is in short supply, and the EU supports the “one-to-five” injection method.
On August 20. The European Medicines Agency, the EU regulator, announced on the 19th that in view of the limited supply of monkeypox vaccine produced by the Nordic company in Bavaria, Denmark, European countries may consider reducing the single dose of the vaccine to expand the scope of vaccination and reduce the number of vaccines.
Vaccination is also effective in preventing infection.
The European Medicines Agency recommends the use of the “one-in-five” injection method, that is, individuals receive two intradermal injections of monkeypox vaccine, about 4 weeks apart, with a single dose of one-fifth of the original dose.
Given the current shortage of monkeypox vaccines, governments may decide to reduce vaccinations as a “temporary measure” to protect susceptible groups, the European Medicines Agency said.
European Commissioner for Health and Food Safety Stella Kyriakidis said in a statement that the injection method could expand the number of people vaccinated against the original monkeypox vaccine in Europe. 5 times, “to ensure that people and health care workers at risk of infection are more likely to receive vaccines.”
The European Medicines Agency’s injection recommendations are based on a controlled study of the performance of different doses of monkeypox vaccine.
In about 500 adults, individuals who received one-fifth of the intradermal dose of the vaccine produced antibody levels similar to those who received the original dose of the vaccine subcutaneously.
The monkeypox vaccine was originally administered subcutaneously.
The European Medicines Agency reminds that individuals are more likely to experience redness and changes in skin color after switching to intradermal injections.
Earlier this month, the U.S. Food and Drug Administration approved a similar injection to expand the vaccine supply.
The practice of splitting vaccines to expand supplies has been used during yellow fever and polio outbreaks, according to the Associated Press.
The Associated Press believes that it is unusual for European and American drug regulatory agencies to recommend “one-to-five” vaccination, indicating that the global monkeypox vaccine is extremely scarce.
According to Reuters, the United Kingdom, Canada and Germany are currently allowing only one dose of the monkeypox vaccine to expand vaccination coverage.
The monkeypox vaccine produced by Nordic Bavaria was originally developed to prevent infection with the smallpox virus. Based on experimental data, the European Medicines Agency approved the vaccine in July to prevent monkeypox virus. The World Health Organization previously estimated that the vaccine was 85 percent effective against monkeypox virus.
The company expects a total supply of 16 million doses of monkeypox vaccine this year.
More than 40,000 monkeypox cases have been reported globally since May, half of them in Europe. WHO declared the monkeypox outbreak a “public health emergency of international concern” on July 23
EU approved one-fifth-dose on Monkeypox vaccination due to shortage
(source:internet, reference only)
Disclaimer of medicaltrend.org
